Recursion Pharmaceuticals, Inc. SEC filings RXRX

Recursion Pharmaceuticals, Inc. has 991 filings in SEC EDGAR's recent list, going back to Apr 2, 2014. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 2, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 2, 2026 (results of operations, officer or director change, regulation fd disclosure). The company's fiscal year ends on December 31.

Form Description Filed Period
ARS Annual report to shareholders Apr 30, 2026 Dec 31, 2025
10-K Annual report Feb 25, 2026 Dec 31, 2025
ARS Annual report to shareholders Apr 28, 2025 Dec 31, 2024
10-K Annual report Feb 28, 2025 Dec 31, 2024
ARS Annual report to shareholders Apr 23, 2024 Dec 31, 2023
10-K Annual report Feb 29, 2024 Dec 31, 2023
ARS Annual report to shareholders Apr 28, 2023 Dec 31, 2022
10-K Annual report Feb 27, 2023 Dec 31, 2022
10-K Annual report Mar 23, 2022 Dec 31, 2021

Showing 9 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
RXRX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Salt Lake City, UT
SEC filer status
Large accelerated filer
SEC CIK
1601830
Former names
Recursion Pharmaceuticals, LLC (until Dec 4, 2015)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.